Resources

Weekly ETF Monitor for week ending 22 February 2019

thumbnail

Feb 25, 2019

This week's highlights Globally, Chinese stocks rebounded last week as well as throughout Asia. Reporting season continued to see mixed results for Australia and the U.S. VanEck’s China focused ETFs CNEW and CETF lead the performance tables for the week. The ETFS Physical Platinum (ETPMPT) was the top performing commodity ETF for the week. Global and domestic bear products were the worst performers over the week as global and domestic markets continued their upward trend from January’s strong rally. Looking longer term, ETFS Physical Palladium (ETPMPD) remains the best performer over 12 months with 57.1% return. The physically backed metal has now reached over US$1,400/oz. Total flows for the week were dominated by cash and fixed income products including AAA, IAF and PLUS. With the ETF market seeing positive inflows of $50.3 million . Trading volumes were again highest among beta ETFs, with Magellan’s MGE making the top 10 for the week.

Download now

Weekly ETF Monitor for week ending 15 February 2019

thumbnail

Feb 19, 2019

This week's highlights Global stocks gained last week with energy, industrials and materials sectors outperforming as U.S./China trade talks progressed. VanEck Vectors China New Economy ETF (CNEW) and ETFS ROBO Global Robotics and Automation ETF (ROBO) were the top performing unleveraged equity funds for the week. High growth plays including RBTZ, CURE and IJR also posted strong gains. Domestic financial sector ETFs were amongst the week's worst-performers as the post-Royal Commission bounce receded; MVB, OZF and QFN all dropped more than 1.4%. Commodity ETFs were mixed with OOO returning 5.4% on reports of lower global oil production. Precious metals mostly declined modestly, with the exception of palladium (ETPMPD), which continued to hit new highs on growing demand and tight supply. Total flows into domestically domiciled ETFs were $54m for the week, while outflows totalled $22m. The week's largest inflows were into a mix of funds including CNEW, BBOZ, HBRD and FAIR. The largest outflows were from GEAR, IEU and IJH. Trading volume was dominated by the usual suspects; STW, VAS, IVV and AAA, with above average trading seen in NDQ, BBOZ and QOZ. ETFS S&P Biotech ETF (CURE) continues to be 2019’s top performing unleveraged equity fund, having gained 18.6% YTD.

Download now

Here's the Buzz around Megatrends

Feb 18, 2019

Here’s the Buzz around Megatrends Products in Focus: The ETF Securities Future Present Range Q4 2018 saw high levels of volatility that particularly affected the tech sector and high beta areas of the market . YTD performance in 2019 has seen a rebound of many of these stocks . In this article we explore some of the key drivers of growth in the future . In the long term there is a positive outlook for technology, robotics, battery tech and biotechnology. At ETF Securities, we often talk about megatrends; disruption, displacement, game-changing and revolutionary technologies. Whilst it is easy to become cynical about the overuse of these terms, it’s clear that the pace of change is accelerating with no signs of slowing. Since 1956 there has been more than a trillion-fold increase in computing power where today the power of the iPhone 6 (an already outdated technology) could theoretically guide 120 million Apollo 11 rockets at once. Taking a step back, the greatest driver of this advancement is simply the enormous expansion in computing power. We now have capabilities to capture and analyse immense quantities of data, and this knowledge is being applied to a wealth of areas, with many of these technologies previously restricted to the realms of science fiction. The ETF Securities Future Present range gives investors a way to access disruptive technologies in a diversified manner. The range includes four funds targeting different sectors that are looking to have a greater presence in the future: TECH: ETFS Morningstar Global Technology ETF Once seen as a highly speculative investment, technology has now firmly cemented its place at the top of the S&P 500. It is fair to say that most people are highly dependent on leading tech firms that have become exceedingly integrated into our lives. We wake up, check the weather on our Apple iPhone, cycle to work on that (pricey) Cannondale and track the ride on our Garmin. Once at the office, the computer is booted up and Microsoft Office provides the tools to get us through the day. These technologies are ubiquitous and as such it is important to know the different ways of gaining exposure to the companies behind them. TECH holds a basket of 32 global technology stocks that have been identified using Morningstar’s moat methodology, meaning they have a competitive advantage over other similar businesses. With Morningstar’s active influence in this fund, it has outperformed the Nasdaq 100 since it was launched in April 2017. ROBO: ETFS ROBO Global Robotics & Automation ETF While the tech sector is dominating the present, it’s robotics, automation and AI (RAAI) that looks set to dominate the future. The outlook for growth in RAAI looks bright and with recent volatility providing increasingly attractive valuations in this sector, is now the time to consider to invest in this thematic? This year industry experts are pointing to improvements in network capabilities, particularly the roll out of 5G networks, aiding growth across the board, with the upgrade from 4 or 4.5G yielding as much as 10-100 time improvements in network speeds. These enhancements are instrumental in enabling the development and implementation of other technologies. Can you imagine using Netflix in the days of dial-up internet? Further penetration of manufacturing robots is also expected to occur as the automation of the workforce continues. Today’s China has approximately 1 robot per 100 manufacturing workers, with huge scope for growth if it’s to reach ratio’s in line with Germany and South Korea’s 6 per 100. These robots are performing monotonous tasks with high levels of precision and increasingly lower costs than their human counterparts, meaning companies will need to keep up with the levels of automation their rivals are using to keep up with the competition. ACDC: ETFS Battery Tech & Lithium ETF Global climate change and the move towards renewable energy is one of the most pressing issues of today and one of the key drivers of our success in addressing this issue will be in the development of energy storage. Imagine a world where battery technology is efficient enough to fly planes and feed power stations – this is the world companies behind this technology are striving for, and we’re already on our way with the explosion of electric vehicle development. But it’s not just electric vehicles making advances. In classic Musk fashion, Elon managed to make batteries the talk of the town in 2018 with his 100-day delivery of the Hornsdale Power Reserve battery in South Australia, currently the largest in the world. This drew attention for the necessity of pairing renewable energy generation with practical storage solutions. Whilst Tesla has had the first-move advantage in the electric vehicle (EV) market, it is rapidly being chased by established car manufacturers like BMW, Volkswagen and Nissan, who have equally ambitious goals to capture the growing consumer demand for green-transport. JP Morgan project EVs and Hybrid Electric Vehicles (HEVs) will account for 30% of all vehicle sales by 2025. CURE: ETFS S&P Biotech ETF Whilst biotechnology is arguably one of the oldest forms of technology, its prospects for future development are high. Since the first smallpox vaccine was administered in 1761, there have been huge advances in the biotechnology field. The sequencing of the first human genome in 2003 enabled a plethora of new biotech drugs to be developed. DNA sequencing has created hope for those previously suffering incurable diseases and has provided a quality of life where it was previously lost. At the time of writing 67 of the 119 stocks in CURE are either researching or producing diagnostic tools or drugs that treat cancer. Therapies are being developed for psychological disorders, inoperable tumours, chronic pain, hereditary diseases and degenerative illnesses. As an industry that is renowned for its volatility, biotechnology can be a particularly difficult sector to choose a winner. For the uninitiated, it is a realm full of highly specific medical jargon, tied up with regulatory barriers and inexplicable results to clinical trials. This is why CURE offers an equal weight and broad exposure to the biotech sector. And whilst it is difficult to know who will be responsible for the next breakthrough treatment, what we do know is that people will always pay for healthcare, especially as our aging population grows. This is an industry where success does not just mean more dollars in the bank, but lives saved, and families kept together. The Future is Now The examples above provide just a glimpse into the full scope of innovation that is captured by the ETF Securities Future Present Range. The future is now, and the way we live and work will continue to be defined by these mega trends. Accessing these sectors through a diversified, equal weight ETF allows investors to take a view on what trends will dictate the times to come.

Download now

Weekly ETF Monitor for week ending 8 February 2019

thumbnail

Feb 12, 2019

This week's highlights The fallout from the Royal Commission was the biggest driver of domestic equity returns last week as most financial stocks rebounded. Financial sector ETFs (OZF, QFN and MVB) all returned in excess of 6% for the week. Bank-heavy domestic dividend-focused ETFs also performed strongly with SYI, FDIV, RDV, ZYAU and VHY all returning more than 4%. Global equities were broadly negative for the week. BetaShares WisdomTree Japan ETF (HJPN), which fell 2.0%, was the poorest performing broad-based international equity fund for the week. The Australian dollar saw significant movement last week, dropping nearly 2c against the US$. YANK returned 6.3%, while AUDS fell 5.2%. Unleveraged funds ZUSD and USD both returned more than 2%. Precious metals continued to outperform, with ETFS Physical Gold (GOLD) up 2.1% and ETFS Physical Palladium (ETPMPD) adding a further 4.3%, taking its 12 month total return to nearly 55%. Oil declined, with OOO dropping 3%. Total flows into domestically domiciled ETFs were $87m for the week, while outflows totalled $61m. The week’s largest inflows were into VanEck’s domestic property and equally-weighted equity funds (MVA and MVW), while the biggest outflows were from QPON and A200. Vanguard Australian Shares ETF (VAS) was the most traded ETF last week, well-exceeding its long-term average turnover. Vanguard MSCI Index International Series (Hedged) (VGAD) also saw notable activity. Three of ETF Securities’ Future Present range of ETFs (CURE, TECH and ROBO) have returned more than 10% YTD in a sign that growth stocks are returning to favour.

Download now

Weekly ETF Monitor for week ending 1 February 2019

thumbnail

Feb 05, 2019

This week's highlights Mining and resources stocks rallied strongly last week. VanEck Vectors Gold Miners ETF (GDX) was the top performing fund for the second week running, returning 5.1%, followed closely by BetaShares Global Gold Miners ETF (MNRS). Domestic resource sector ETFs (QRE, OZR ad MVR) were also amongst the top performers. Domestic financial sector ETFs fell in advance of the release of the Hayne Royal Commission findings this week; MVB, OZF and QFN all dropped more than 3.5%. Commodity ETFs generally had a strong week with oil (OOO), hedged gold (QAU) and silver (ETPMAG) all amongst the top performers. All five ETF Securities’ precious metals funds posted positive returns for the week. Total flows into domestically domiciled ETFs were $193m for the week, while outflows totalled only $10m. The weeks largest inflows were into domestic equities (IOZ), A$ cash (BILL) and iShares Global Consumer Staples ETF (IXI). Major domestic benchmark ETFs dominated trading volume last week. IXI, IAF, BILL and IXJ all seeing above average trading levels. ETFS S&P Biotech ETF (CURE) has returned 13.0% in 2019 to-date, making it the top performing unleveraged equity ETF.

Download now

Weekly ETF Monitor for week ending 25 January 2019

thumbnail

Jan 30, 2019

This week's highlights Global stocks were mixed last week with gold miners, real estate and non-Japan Asia outperforming. VanEck Vectors Gold Miners ETF (GDX) was the top performing fund for the week, returning 3.7%, followed by iShares MSCI South Korea Capped ETF (IKO) at 3.5%. Global energy and healthcare funds were amongst the poorest performers with FUEL, IXJ, CURE and DRUG all posting negative weeks. Australian financial sector ETFs also declined. Inflows were also mixed with money moving into both long and short domestic equity funds (BBOZ, STW and EX20), global infrastructure (IFRA) and multifactor ETFs (WDMF and EMKT). Outflows were primarily from domestic financial sectors (QFN), geared equity funds (GEAR and GGUS) and Europe (IEU). Both BetaShares Australian High Interest Cash ETF (AAA) and BetaShares Australian Bank Snr Floating Rate Bond ETF (QPON) saw significant trading volume last week, while volumes in major equity benchmarks were well below longer-term averages.

Download now